Cyclosporin A-related cerebral venous sinus thrombosis
A case report

Fengjuan Gao, MD\textsuperscript{a,b}, Jun Zhang, MD\textsuperscript{a,b}, Fang Wang, MD\textsuperscript{a,b}, Xiaoyan Xin, MD\textsuperscript{b,c}, Dujuan Sha, MD, PhD\textsuperscript{a,b,*}

Abstract

Rationale: Cerebral venous sinus thrombosis (CVST) is a complex life-threatening condition, and its etiology is not well understood. Although oral cyclosporin A is not a common cause of the symptoms related to CVST, there is limited information available.

Patient concerns: In this study, we report a rare case of CVST in a 44-year-old woman with aplastic anemia, who was given cyclosporin A orally for a period of 18 months. She had experienced a headache for 20 days.

Diagnoses: The patient was diagnosed with CVST by computed tomography venography.

Interventions: Low molecular heparin (enoxaparin, 4000 AXaIU, subcutaneous injection, once every 12 hours) was administered for anticoagulation.

Outcomes: The patient developed no recurrence of thrombosis during the 13-month follow-up period.

Lessons: Clinicians should be aware of the possibility of CVST when patients are treated with cyclosporin A and have symptoms such as headaches.

Abbreviations: AA = aplastic anemia, CT = computed tomography, CTV = computed tomography venography, CVST = cerebral venous sinus thrombosis, MRV = magnetic resonance venography.

Keywords: cerebral venous sinus thrombosis, cyclosporin A, headache

1. Introduction

The etiology of cerebral venous sinus thrombosis (CVST) is complex, involving hereditary, and acquired factors, according to a report by Alvis-Miranda et al.\textsuperscript{[1]} CVST due to hereditary factors is rare, while CVST resulting from acquired factors is commonly observed. Acquired factors mainly include brain tumors, brain trauma, infection of the nervous system, immune system diseases, and drugs. Oral contraceptives are the most common drugs responsible for causing CVST.\textsuperscript{[2]}

Although rare, other drugs, such as cyclosporin A and tacrolimus, have been reported to cause CVST.\textsuperscript{[1]} Here, we report a rare case of CVST in a 44-year-old woman, who was administered cyclosporin A orally for 18 continuous months.

2. Case report

A 44-year-old woman presented to our hospital with symptoms of a headache for 20 days and weakness in the right limbs for 1 day. She had a history of aplastic anemia (AA) and had been taking 130 mg oral cyclosporin A (twice a day) continuously for 18 months. Physical examination was performed and the following parameters were noted: height, 170 cm; weight, 68 kg; body temperature, 36.5°C; and blood pressure, 142/83 mm Hg. No abnormality was observed on cardiopulmonary or abdominal examination. Neurological examination revealed conscious mind and motor aphasia; bilateral eye movement was flexible; size of the bilateral pupils were equal at 3 mm in diameter; light reflex was observed; the right nasolabial sulcus was shallow; tongue was in the middle; gag reflex was noted; neck was soft; according to the manual muscle test, the strength level of the right upper and lower limb muscles was 5 (normal); muscle tension in all limbs was normal and physiological reflex was noted; and the Babinski sign on the right side was positive. The patient had no history of diabetes, hypertension, hyperlipidemia, liver cirrhosis, smoking, use of contraceptive pills, pregnancy, puerperium, and infection. Laboratory examination revealed: white blood cells, 6.19 \times 10^{3}/L (normal reference value 4–10 \times 10^{3}/L); neutrophils, 86.9% (normal reference value 50–70%);; hemoglobin, 89 g/L (normal reference value for adult female 110–150 g/L); platelets 55 \times 10^{3}/L (normal reference value 100–300 \times 10^{3}/L); blood concentration of cyclosporin A (valley concentration), 240.7 μg/L.

Editor: N/A.

This report was supported by the National Natural Science Foundation of China (81571122).

The authors have no conflicts of interest to disclose.

\* Correspondence: Dujuan Sha, Department of Emergency, Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School, 321 Zhongshan Road, Nanjing 210008, Jiangsu, China (e-mail: tbswen0912@126.com).

© Copyright 2018 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2018) 97:31(e11642)

Received: 9 January 2018 / Accepted: 28 June 2018

http://dx.doi.org/10.1097/MD.0000000000011642
g/L (normal reference value 150–250 μg/L); plasma D dimer, 31.38 mg/L (normal reference value < 0.5 mg/L); and normal levels of blood protein S, protein C, antithrombin III antibody, immune indexes, indexes of tumor, homocysteine, and blood fibrin. Ischemia and hemorrhage were observed in left frontal lobe by computed tomography (CT) scan (Fig. 1A). There was no abnormality in the cerebral arteries (Fig. 1B) and sinus thrombosis was observed in the superior sagittal sinus by computed tomography venography (CTV) (Fig. 1C). The patient was administered low molecular heparin (enoxaparin, 4000 AXaIU, subcutaneous injection, once every 12 hours) for anticoagulation. After 2 weeks, it was replaced by warfarin, and the dosage of warfarin was adjusted by the international normalized ratio (2.0–2.5). Cyclosporin A was stopped immediately and replaced by Testosterone Undecanoate. After 30 days, the patient had no more thrombosis. But her hemoglobin concentration was declined to 55 g/L. According to the hematology specialists and neurologists’ comments, cyclosporine A was resumed again and warfarin was taken together. The dosage of cyclosporine A was adjusted between 100 to 150 mg (twice a day) according to the blood concentration. The patient developed no recurrence of thrombosis during the 13-month follow-up.

3. Discussion

CVST is a type of cerebrovascular disease, the incidence of which is < 1% among all stroke cases.\[^{4}\] It has been reported that the main risk factors for CVST include oral contraceptives, pregnancy, postpartum complications, trauma, and a hypercoagulable state.\[^{11}\] In addition to oral contraceptives, CVST can be caused by other drugs, such as immunosuppressants and cortical hormones.\[^{3,12}\] Table 1.\[^{1}\]

Headache is the most common clinical manifestation of CVST. Furthermore, seizures, subarachnoid hemorrhage, intracranial hypertension, and coma have been noted as symptoms in a few patients.\[^{28–30}\] Since the clinical manifestations of CVST lack specificity, misdiagnosis or underdiagnosis commonly occurs in clinical practice. Currently, cerebral magnetic resonance venography (MRV) is the best diagnostic method for CVST.\[^{31,32}\] In addition, the use of cerebral CTV is feasible, if the patient is unfit to undergo MRV. In the initial stage in our case, headache and vomiting occurred; however, no abnormal symptoms were noted on physical examination. In addition, cerebral CT or cerebral magnetic resonance imaging findings were normal. Cerebral CTV aided in the final diagnosis. Thus, for patients who are suspected to have CVST, it is suggested that cerebral MRV or CTV is performed at the earliest opportunity.

CVST can also occur as a secondary disease after intracerebral hemorrhage; this is one of the reasons for the misdiagnosis of CVST. The cerebral CT scan of our patient revealed intracerebral hemorrhage; however, on CTV, it was soon discovered to be a result of CVST. Therefore, anticoagulant therapy was promptly administered. According to the 2010 European Federation of Neurological Societies guidelines,\[^{4}\] intracerebral hemorrhage is not a contraindication of anticoagulant therapy in CVST. Although CVST itself can be serious, the use of anticoagulant drugs can also aggravate intracerebral hemorrhage. Furthermore, to safely perform anticoagulant therapy in patients with early intracerebral hemorrhage associated with CVST, the therapeutic decision should be individualized to the patient and caution should be taken.\[^{33}\]

Cyclosporin A, a specific immune inhibitor, is now recognized as the first-line drug in the treatment of AA in adults. There are few reports on CVST induced by cyclosporin A.\[^{3,11,12}\] Its mechanism is remains unclear. According to the medical history and examination results, the patient had no cerebral trauma, intracranial surgery, central nervous system infection, facial abscess, tumor, autoimmune disease, other oral drugs, puerperium, pregnancy, hypercoagulable state, or hereditary diseases; therefore, other possible causes of CVST had been ruled out. Anemia is the main symptom of AA. Anemia can also predispose to CVST. But it was reported that cyclosporin A can induce CVST, especially in patients with severe anemia (hemoglobin < 5.0 mmol/L for nonpregnant women) and no association with mild anemia. In this patient, the hemoglobin concentration is 89 g/L (5.52 mmol/L). Thus, we consider the patient to have had CVST induced by Cyclosporin A. Cyclosporin A inhibits the release of prostacyclin from vascular endothelial cells, activates the renin–angiotensin system, increases the synthesis of systolic vascular endothelia and thromboxane A2, and increases production of free radicals; thus, this directly leads to endothelial injury and vasomotor function damage.\[^{36}\] In addition, cyclosporin A can activate the endogenous coagulation pathway\[^{37}\] and induce the expression of inducible nitric oxide synthase.\[^{38}\] These factors are considered to be the main mechanisms through which thrombosis is induced by cyclosporin A. According to the literature report, the time ranges of cyclosporine A induced CVST is from 9 days to 11 months.\[^{3,11,12}\] and our patient had taken cyclosporine A for 18 months. Therefore, the specific time for cyclosporine A induced
CVST is unclear. We also noticed that the time of intravenous cyclosporin A induced CVST is shorter than that of oral cyclosporine A. The fastest time of the former is 9 days. Whether it is related to the rapid increase of blood concentration of intravenous cyclosporin A, it is not reported up to present. Patients should be informed about the possibility of CVST and caution should be taken for patients who experience headaches when being treated with oral cyclosporin A. Early diagnosis is important, such that prompt therapy can be administered to improve the prognosis of patients and reduce mortality and morbidity.

Acknowledgments

The authors thank the assistance from our colleagues at the Department of Hematology of Nanjing Drum Tower Hospital. The authors thank Editage (www.editage.com) for English language editing.

Author contributions

Data curation: Jun Zhang, Fang Wang.
Methodology: Xiaoyan Xin.
Writing – original draft: Fengjuan Gao.
Writing – review and editing: Dujuan Sha.

References

[1] Alvis-Miranda HR, Castellar-Leones SM, Alcala-Cerra G, et al. Cerebral sinus venous thrombosis. J Neurourol Rural Pract 2013;4:427–38.
[2] Özdinler HH, Varol S, Akal E, et al. Evaluation of cerebral venous sinus thrombosis secondary to oral contraceptive use in adolescents. Neurrol Sci 2015;36:149–53.
[3] Rajapakse S, Gnanajothy R, Lokumarangoda N, et al. A kidney transplant patient on cyclosporine therapy presenting with dural venous sinus thrombosis: a case report. Cases J 2009;2:9139.
[4] Einhaupl K, Stum J, Bousser MG, et al. European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neuroul 2010;17:1229–35.
[5] Meng R, Ji X, Wang X, et al. The etiologies of new cases of cerebral venous sinus thrombosis reported in the past year. Intractable Rare Dis Res 2012;1:23–6.

[6] Rothwell PM, Grant R. Cerebral venous sinus thrombosis induced by “ecstasy”. J Neurol Neurosurg Psychiatry 1993;56:1035.

[7] Hitosugi M, Kitamura O, Takatani A, et al. A case of dural sinus thrombosis during the medication of medroxyprogesterone acetate. Nihon Hoigaku Zasshi 1997;51:452–6.

[8] Wasay M, Baboki R, Kojan S, et al. Superior sagittal sinus thrombosis due to lithium: local urokinase thrombolysis treatment. Neurology 2000;54:532–3.

[9] Chu K, Kang DW, Kim DE, et al. Cerebral venous thrombosis associated with tentorial subdural hematoma during oxymetholone therapy. J Neurol Sci 2001;185:27–30.

[10] Sahraian MA, Mottamed M, Azimi AR, et al. Androgen-induced cerebral venous sinus thrombosis in a young body builder: case report. BMC Neurol 2004;4:22.

[11] Murata S, Ishikawa N, Oshikawa S, et al. Cerebral venous sinus thrombosis associated with severe active ulcerative colitis. Intern Med 2004;43:460–3.

[12] Al-Shekhlee A, Oghlakian G, Katirji B. A case of cyclosporin-induced dural sinus thrombosis. J Thromb Haemost 2005;3:1327–8.

[13] Lenz RA, Saver J. Venous sinus thrombosis in a patient taking thalidomide. Cerebrovasc Dis 2004;18:175–7.

[14] Guimarães J, Azevedo E. Phytoestrogens as a risk factor for cerebral sinus thrombosis. Cerebrovasc Dis 2005;20:137–8.

[15] Dunne C, Malvyk D, Fireo T. Cerebral venous sinus thrombosis in a woman using the etonogestrel-ethinyl estradiol vaginal contraceptive ring: a case report. J Obstet Gynaecol Can 2010;32:270–5.

[16] Kolicak C, Rococo V. The combined vaginal contraceptive ring, nuvaring, and cerebral venous sinus thrombosis: a case report and review of the literature. J Emerg Med 2012;42:413–6.

[17] Tsoji Y, Nakayama T, Bono K, et al. Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan. Rinsho Shinkeigaku 2014;54:423–8.

[18] Ruffa A, Cerase A, Monti L, et al. Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction. J Neurol Sci 2007;260:293–5.

[19] Mahadeo KM, Dhall G, Panigrahy A, et al. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methyleneetrahydrofolate reductase (MTHFR) C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity via direct endothelial injury. Pediatr Hematol Oncol 2010;27:46–52.

[20] Wani NA, Kosar T, Pala NA, et al. Sagittal sinus thrombosis due to L-asparaginase. J Pediatr Neurosci 2010;5:32–5.

[21] Alsaid Y, Gulab S, Bayoumi M, et al. Cerebral sinus venous thrombosis due to asparaginase therapy. Case Rep Hematol 2013;2013:841057.

[22] Akdal G, Dommez B, Cakmakci H, et al. A case with cerebral thrombosis receiving tamoxifen treatment. Eur J Neurol 2001;8:723–4.

[23] Kim Y, Kim OJ, Kim J. Cerebral venous thrombosis in a breast cancer patient taking tamoxifen: report of a case. Int J Surg Case Rep 2015;6:77–80.

[24] Hwang SK. A case of dural arteriovenous fistula of superior sagittal sinus after tamoxifen treatment for breast cancer. J Korean Neurosurg Soc 2015;57:204–7.

[25] Gazioglu S, Solmaz D, Boz C. Cerebral venous thrombosis after high dose steroid in multiple sclerosis: a case report. Hippokratia 2013;17:88–90.

[26] Benadiba J, Robtaille N, Lambert G, et al. Intravenous immunoglobulin-associated thrombosis: is it such a rare event? Report of a pediatric case and of the Quebec Hemovigilance System. Transfusion 2015;55:571–5.

[27] Fesler MJ, Greer MH, Richart JM, et al. Heparin-induced thrombocytopenia and cerebral venous sinus thrombosis: case report and literature review. Neurocrit Care 2011;15:161–5.

[28] Ferro JM, Canhao P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664–70.

[29] De Bruijn SF, Stam J, Kappelle LJ. thunderclap headache as first symptom of cerebral venous sinus thrombosis. CVST Study Group. Lancet 1996;348:1623–5.

[30] Cantu C, Barraclough F, Farnell L, et al. Association between thiopental anesthesia and cerebral venous sinus thrombosis: case report and literature review. Neurocrit Care 2011;15:161–5.

[31] Ferro JM, Canhao P. Cerebral venous sinus thrombosis: update on diagnosis and management. Curr Cardiol Rep 2014;16:523.

[32] Masuhr F, Mehraein S, Einhaupl K. Cerebral venous and sinus thrombosis. J Neurol 2004;251:11–18.

[33] Coutinho JM, Zuurbier SM, Gaartman AE, et al. Association between MTHFR C677T polymorphism: homocysteine-mediated methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old girl with acute lymphoblastic leukemia and methyleneetrahydrofolate reductase (MTHFR) C677T polymorphism. J Neurol Neurosurg Psychiatry 2002;73:277–81.

[34] Tomasiak M, Rusak T, Gacko M, et al. Association between MTHFR C677T polymorphism and cerebral venous sinus thrombosis: case report and literature review. Neurocrit Care 2011;15:161–5.

[35] Stolz E, Valdueza JM, Grebe M, et al. Anemia as a risk factor for cerebral venous thrombosis? An old hypothesis revisited. Results of a prospective study. J Neurol 2007;254:729–34.

[36] Coutuño JM, Zaurier SM, Gaertman AE, et al. Association between anemia and cerebral venous thrombosis: case–control study. Stroke 2015;46:2735–40.

[37] Päpachristou F, Papadimitropoulos A, Kotsantis P, et al. Interaction of endothelin-1 and nitric oxide pathways in human tubular epithelial cells under the influence of cyclosporin-A. Ren Fail 2010;32:727–32.